Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors

R. Kefford, H. Arkenau, M. P. Brown, M. Millward, J. R. Infante, G. V. Long, D. Ouellet, M. Curtis, P. F. Lebowitz, G. S. Falchook

Research output: Contribution to journalMeeting abstractpeer-review

Original languageEnglish
Pages (from-to)8503–8503
Number of pages1
JournalJournal of Clinical Oncology
Issue number15
Publication statusPublished - 20 May 2010

Cite this